NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/09/2024
Back to search
Official data from USPTO
TPU PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
01/09/2024
Trademark type
Word
Nice classes
5
Filing date
10/12/2020
Registration date
01/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/09/2024
Last transaction
01/09/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
11/13/2023
First use in commerce
11/13/2023
Drawing code
4
Owner type
03
Owner location
San Jose, CA, US
Examiner
HSU, FONG
Law office
O20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Teikoku Pharma USA, Inc.
Representatives
Bret E. Field BOZICEVIC, FIELD & FRANCIS LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals for the treatment of cardiovascular conditionsallergiescentral nervous system conditionsperipheral nervous system conditionselectrolytic imbalancecaloric imbalanceobesityvitamin imbalancegastrointestinal conditionsinflammationdermatological conditionsinfectious diseaseshormonal imbalancepaincancer conditionspulmonary conditionsophthalmic conditionsmusculoskeletal conditionsdiabetic conditionspsychosissenile conditionsdementiacongenital disease conditionsabnormal gene conditions; pharmaceutical preparationscompositionscreams and lotions for the treatment of cardiovascular conditionsallergiescentral nervous system conditionsperipheral nervous system conditionselectrolytic imbalancecaloric imbalanceobesityvitamin imbalancegastrointestinal conditionsinflammationdermatological conditionsinfectious diseaseshormonal imbalancepaincancer conditionspulmonary conditionsophthalmic conditionsmusculoskeletal conditionsdiabetic conditionspsychosissenile conditionsdementiacongenital disease conditionsabnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditionsallergiescentral nervous system conditionsperipheral nervous system conditionselectrolytic imbalancecaloric imbalanceobesityvitamin imbalancegastrointestinal conditionsinflammationdermatological conditionsinfectious diseaseshormonal imbalancepaincancer conditionspulmonary conditionsophthalmic conditionsmusculoskeletal conditionsdiabetic conditionspsychosissenile conditionsdementiacongenital disease conditionsabnormal gene conditions; prescription and over-the-counter pharmaceutical preparationstransdermal gel formulationstransdermal cream formulationsoral mucous formulationstransdermal patchesdressings and medical adhesive tapes for use in the treatment of cardiovascular conditionsallergiescentral nervous system conditionsperipheral nervous system conditionselectrolytic imbalancecaloric imbalanceobesityvitamin imbalancegastrointestinal conditionsinflammationdermatological conditionsinfectious diseaseshormonal imbalancepaincancer conditionspulmonary conditionsophthalmic conditionsmusculoskeletal conditionsdiabetic conditionspsychosissenile conditionsdementiacongenital disease conditionsabnormal gene conditions; pharmaceutical productsanalgesics
Publications
History of USPTO decisions and trademark events.
47 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/09/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/08/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/07/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/01/2023
DPCC
DIVISIONAL PROCESSING COMPLETE
12/01/2023
DRRR
DIVISIONAL REQUEST RECEIVED
11/29/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/27/2023
IUAF
USE AMENDMENT FILED
11/14/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
11/14/2023
EISU
TEAS STATEMENT OF USE RECEIVED
11/14/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/11/2023
EX4G
SOU EXTENSION 4 GRANTED
05/09/2023
EXT4
SOU EXTENSION 4 FILED
05/09/2023
EEXT
SOU TEAS EXTENSION RECEIVED
05/09/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/17/2022
EX3G
SOU EXTENSION 3 GRANTED
11/15/2022
EXT3
SOU EXTENSION 3 FILED
11/15/2022
EEXT
SOU TEAS EXTENSION RECEIVED
11/15/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/18/2022
EX2G
SOU EXTENSION 2 GRANTED
05/16/2022
EXT2
SOU EXTENSION 2 FILED
05/16/2022
EEXT
SOU TEAS EXTENSION RECEIVED
05/16/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/13/2021
EX1G
SOU EXTENSION 1 GRANTED
11/11/2021
EXT1
SOU EXTENSION 1 FILED
11/11/2021
EEXT
SOU TEAS EXTENSION RECEIVED
11/11/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/18/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/23/2021
PUBO
PUBLISHED FOR OPPOSITION
03/23/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/16/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
02/16/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/16/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
02/16/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/16/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
02/06/2021
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
02/02/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/15/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
01/14/2021
ALIE
ASSIGNED TO LIE
01/14/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/13/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
01/13/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/13/2021
DOCK
ASSIGNED TO EXAMINER
01/08/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/28/2020
NWAP
NEW APPLICATION ENTERED
10/15/2020
Continuous trademark protection
Get notified about every new filing that threatens TPU PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.